392 related articles for article (PubMed ID: 25911104)
1. Tumor-suppressive p53 Signaling Empowers Metastatic Inhibitor KLF17-dependent Transcription to Overcome Tumorigenesis in Non-small Cell Lung Cancer.
Ali A; Bhatti MZ; Shah AS; Duong HQ; Alkreathy HM; Mohammad SF; Khan RA; Ahmad A
J Biol Chem; 2015 Aug; 290(35):21336-51. PubMed ID: 25911104
[TBL] [Abstract][Full Text] [Related]
2. KLF17 empowers TGF-β/Smad signaling by targeting Smad3-dependent pathway to suppress tumor growth and metastasis during cancer progression.
Ali A; Zhang P; Liangfang Y; Wenshe S; Wang H; Lin X; Dai Y; Feng XH; Moses R; Wang D; Li X; Xiao J
Cell Death Dis; 2015 Mar; 6(3):e1681. PubMed ID: 25766320
[TBL] [Abstract][Full Text] [Related]
3. Gain-of-function of mutant p53: mutant p53 enhances cancer progression by inhibiting KLF17 expression in invasive breast carcinoma cells.
Ali A; Shah AS; Ahmad A
Cancer Lett; 2014 Nov; 354(1):87-96. PubMed ID: 25111898
[TBL] [Abstract][Full Text] [Related]
4. NT5DC2 suppression restrains progression towards metastasis of non-small-cell lung cancer through regulation p53 signaling.
Jin X; Liu X; Zhang Z; Xu L
Biochem Biophys Res Commun; 2020 Dec; 533(3):354-361. PubMed ID: 32962856
[TBL] [Abstract][Full Text] [Related]
5. Krüppel-like factor 17, a novel tumor suppressor: its low expression is involved in cancer metastasis.
Zhou S; Tang X; Tang F
Tumour Biol; 2016 Feb; 37(2):1505-13. PubMed ID: 26662959
[TBL] [Abstract][Full Text] [Related]
6. Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer.
Chowdhury P; Dey P; Ghosh S; Sarma A; Ghosh U
BMC Cancer; 2019 Aug; 19(1):829. PubMed ID: 31438892
[TBL] [Abstract][Full Text] [Related]
7. MiR-182 inhibits the epithelial to mesenchymal transition and metastasis of lung cancer cells by targeting the Met gene.
Li Y; Zhang H; Li Y; Zhao C; Fan Y; Liu J; Li X; Liu H; Chen J
Mol Carcinog; 2018 Jan; 57(1):125-136. PubMed ID: 28940757
[TBL] [Abstract][Full Text] [Related]
8. Repression of TIF1γ by SOX2 promotes TGF-β-induced epithelial-mesenchymal transition in non-small-cell lung cancer.
Wang L; Yang H; Lei Z; Zhao J; Chen Y; Chen P; Li C; Zeng Y; Liu Z; Liu X; Zhang HT
Oncogene; 2016 Feb; 35(7):867-77. PubMed ID: 25961934
[TBL] [Abstract][Full Text] [Related]
9. The CD44high Subpopulation of Multifraction Irradiation-Surviving NSCLC Cells Exhibits Partial EMT-Program Activation and DNA Damage Response Depending on Their p53 Status.
Pustovalova M; Alhaddad L; Blokhina T; Smetanina N; Chigasova A; Chuprov-Netochin R; Eremin P; Gilmutdinova I; Osipov AN; Leonov S
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673439
[TBL] [Abstract][Full Text] [Related]
10. Cathepsin L activated by mutant p53 and Egr-1 promotes ionizing radiation-induced EMT in human NSCLC.
Wang W; Xiong Y; Ding X; Wang L; Zhao Y; Fei Y; Zhu Y; Shen X; Tan C; Liang Z
J Exp Clin Cancer Res; 2019 Feb; 38(1):61. PubMed ID: 30732622
[TBL] [Abstract][Full Text] [Related]
11. Krüppel-like factor 17 inhibits urokinase plasminogen activator gene expression to suppress cell invasion through the Src/p38/ MAPK signaling pathway in human lung adenocarcionma.
Cai XD; Che L; Lin JX; Huang S; Li J; Liu XY; Pan XF; Wang QQ; Chen L; Lin MJ; Huang ZH; Ma HM; Wu Y; Liu SM; Zhou YB
Oncotarget; 2017 Jun; 8(24):38743-38754. PubMed ID: 28454121
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of M2 AChR/NF-κB signaling axis reverses epithelial-mesenchymal transition (EMT) and suppresses migration and invasion in non-small cell lung cancer (NSCLC).
Zhao Q; Yue J; Zhang C; Gu X; Chen H; Xu L
Oncotarget; 2015 Oct; 6(30):29335-46. PubMed ID: 26336823
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of ELF3 facilitates cell growth and metastasis through PI3K/Akt and ERK signaling pathways in non-small cell lung cancer.
Wang H; Yu Z; Huo S; Chen Z; Ou Z; Mai J; Ding S; Zhang J
Int J Biochem Cell Biol; 2018 Jan; 94():98-106. PubMed ID: 29208568
[TBL] [Abstract][Full Text] [Related]
14. Tumor-suppressive effects of microRNA-181d-5p on non-small-cell lung cancer through the CDKN3-mediated Akt signaling pathway in vivo and in vitro.
Gao LM; Zheng Y; Wang P; Zheng L; Zhang WL; Di Y; Chen LL; Yin XB; Tian Q; Shi SS; Xu SF
Am J Physiol Lung Cell Mol Physiol; 2019 May; 316(5):L918-L933. PubMed ID: 30628487
[TBL] [Abstract][Full Text] [Related]
15. KIAA1199 promotes invasion and migration in non-small-cell lung cancer (NSCLC) via PI3K-Akt mediated EMT.
Tang Z; Ding Y; Shen Q; Zhang C; Li J; Nazar M; Wang Y; Zhou X; Huang J
J Mol Med (Berl); 2019 Jan; 97(1):127-140. PubMed ID: 30478628
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation.
Bao L; Diao H; Dong N; Su X; Wang B; Mo Q; Yu H; Wang X; Chen C
Cell Biol Toxicol; 2016 Dec; 32(6):469-482. PubMed ID: 27423454
[TBL] [Abstract][Full Text] [Related]
17. Pathologically decreased expression of miR-193a contributes to metastasis by targeting WT1-E-cadherin axis in non-small cell lung cancers.
Chen J; Gao S; Wang C; Wang Z; Zhang H; Huang K; Zhou B; Li H; Yu Z; Wu J; Chen C
J Exp Clin Cancer Res; 2016 Nov; 35(1):173. PubMed ID: 27821145
[TBL] [Abstract][Full Text] [Related]
18. FMNL1 down-regulation suppresses bone metastasis through reducing TGF-β1 expression in non-small cell lung cancer (NSCLC).
Yang XY; Liao JJ; Xue WR
Biomed Pharmacother; 2019 Sep; 117():109126. PubMed ID: 31387165
[TBL] [Abstract][Full Text] [Related]
19. Autophagic secretion of HMGB1 from cancer-associated fibroblasts promotes metastatic potential of non-small cell lung cancer cells via NFκB signaling.
Ren Y; Cao L; Wang L; Zheng S; Zhang Q; Guo X; Li X; Chen M; Wu X; Furlong F; Meng Z; Xu K
Cell Death Dis; 2021 Sep; 12(10):858. PubMed ID: 34552063
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia‑induced internalization of connexin 26 and connexin 43 in pulmonary epithelial cells is involved in the occurrence of non‑small cell lung cancer via the P53/MDM2 signaling pathway.
Zeng SG; Lin X; Liu JC; Zhou J
Int J Oncol; 2019 Oct; 55(4):845-859. PubMed ID: 31485592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
